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A B S T R A C T
Purpose
Although most hospital-based studies suggest more favorable survival with tumor-infiltrating
lymphocytes (TILs) present in primary melanomas, it is uncertain whether TILs provide prognostic
information beyond existing melanoma staging definitions. We addressed the issue in an
international population-based study of patients with single and multiple primary melanomas.
Patients and Methods
On the basis of the Genes, Environment and Melanoma (GEM) study, we conducted follow-up of
2,845 patients diagnosed from 1998 to 2003 with 3,330 invasive primary melanomas centrally
reviewed for TIL grade (absent, nonbrisk, or brisk). The odds of TIL grades associated with
clinicopathologic features and survival by TIL grade were examined.
Results
Independent predictors (P  .05) for nonbrisk TIL grade were site, histologic subtype, and Breslow
thickness, and for brisk TIL grade, they were age, site, Breslow thickness, and radial growth
phase. Nonbrisk and brisk TIL grades were each associated with lower American Joint Committee
on Cancer (AJCC) tumor stage compared with TIL absence (Ptrend  .001). Death as a result of
melanoma was 30% less with nonbrisk TIL grade (hazard ratio [HR], 0.7; 95% CI, 0.5 to 1.0) and
50% less with brisk TIL grade (HR, 0.5; 95% CI, 0.3 to 0.9) relative to TIL absence, adjusted for
age, sex, site, and AJCC tumor stage.
Conclusion
At the population level, higher TIL grade of primary melanoma is associated with a lower risk of
death as a result of melanoma independently of tumor characteristics currently used for AJCC
tumor stage. We conclude that TIL grade deserves further prospective investigation to determine
whether it should be included in future AJCC staging revisions.
J Clin Oncol 31:4252-4259. © 2013 by American Society of Clinical Oncology
INTRODUCTION
Classification of melanoma stage is based on pathol-
ogy features of the primary tumor and spread of
disease at the time of diagnosis. Stage is a major
contributor to treatment decision making. The
primary tumor characteristics used in the most re-
cent version of the AJCC/UICC-TNM staging
system (American Joint Committee on Cancer/In-
ternational Union Against Cancer–Tumor-Node-
Metastasis) for melanoma are Breslow thickness,
ulceration, and mitoses.1 Presence of tumor-
infiltrating lymphocytes (TILs) in the primary mel-
anoma is not currently included in AJCC tumor
staging. TILs are lymphocytes that infiltrate tumors
and disrupt the tumor cells, and they are scored as
absent, nonbrisk, or brisk.2-4 Although several
hospital- or clinic-based studies3,5-9 indicate that
TILs in primary melanomas predict better patient
survival, it is uncertain whether TILs add informa-
tion to present melanoma staging.
A higher TIL grade has been found to be more
common in younger patients10 and thinner melano-
mas,2,5,8,10,11 but less common with higher mitotic
rate or ulceration,8,9 although others found no
correlation with mitoses or ulceration.11 One
population-based study of primary melanomas re-
ported no melanoma-specific survival advantage for
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the presence of TILs.12 Several hospital- or clinic-based studies found
TILs associated with better overall5,7 and melanoma-specific sur-
vival3,6,8,9 adjusted for other prognostic factors; however, all were
selected on the basis of referral to a particular center, and most applied
additional selection criteria, such as excluding patients with melano-
mas less than 0.75 mm thick,6-8 including only patients in clinical
trials,5-7 or including only patients age 65 years or older at diagnosis.9
The majority included only vertical growth phase melanomas.3,5-7,9-11
We examined TIL grade in the large, population-based Genes,
Environment and Melanoma (GEM) study of patients with single
primary melanomas (SPMs) and multiple primary melanomas
(MPMs). GEM study patients were diagnosed from 1998 to 2003 and
had centralized review of histopathology characteristics of their mela-
nomas, including TIL grade, and follow-up for survival.13-15 The GEM
study has allowed us to characterize more clearly the pathology fea-
tures and AJCC tumor staging associated with TIL grades and to




The GEM study included patients from Australia, Italy, Canada, and
the United States who had single and multiple primary cutaneous
melanomas.13-15 Patients with an SPM were diagnosed in 2000 and those with
MPMs were diagnosed with a second or higher-order invasive or in situ
melanoma from 1998 to 2003 (these were the index melanomas); MPMs were
over-represented by design for purposes other than this analysis. In addition to
the index melanomas, we searched for the previous (usually the first) mela-
noma for patients with MPMs in local cancer registry records. The institu-
tional review boards at the coordinating center, Memorial Sloan-Kettering
Cancer Center, and at each participating institution approved the study pro-
tocol. Physician approval was obtained before contacting eligible participants,
and all study participants provided informed consent for obtaining diagnostic
slides of their index and previous melanoma(s) (for patients with MPMs) for
centralized review.
In GEM, there were 3,578 participants with a total of 4,784 primary
melanomas. In situ melanomas were eligible as index MPMs when the patient
had a previous invasive melanoma, but were excluded (n  302) from this
study because we sought to investigate TILs in relationship to the clinicopath-
ologic features of and survival from invasive melanomas. This analysis in-
cluded only primary invasive melanomas centrally scored for TIL grade by
study dermatopathologists. They comprised 1,919 index SPMs (81% of 2,372),
673 index MPMs (74% of 904), and 738 previous MPMs (61% of 1,206)—
3,330 melanomas in all (74% of 4,482) diagnosed in 2,845 (80% of 3,578)
GEM participants (Table 1). The 673 index MPMs and 738 previous MPMs
had occurred in 926 index patients with MPMs (77% of 1,206): 188 with
pathology reviewed for only the index MPM, 253 for only the previous MPM,
and 485 for both.
Pathology Review
Patients’ age and sex and body sites of the melanomas were extracted
from pathology reports and confirmed during patient interview; histologic
subtype and Breslow thickness were also extracted from pathology reports.
Standardized pathology review of the melanoma slides recorded histologic
subtype, Breslow thickness, mitoses, ulceration, and radial or vertical growth
phase. Melanomas were classified according to published histopathology cri-
teria.16,17 Mitoses were recorded as present or absent.18
TIL grade was scored as absent, nonbrisk, or brisk by using a previously
defined grading system.2-4 The reviewers were blind to melanoma outcome. In
a test set of 19 sections scored for TIL grade by the three dermatopathologists
who reviewed the GEM melanomas, the  statistic for agreement on nominal
response between the pathologists was 0.77, which indicates good agreement.
All data items were available for the T classification describing the state of
the primary tumor in the AJCC TNM (tumor, regional nodes, distant metas-
tasis) melanoma staging system1; data on regional nodal and distant metasta-
ses were not available.
Information about deaths from melanoma or other causes was obtained
for all participants from National Death Indexes, cancer registries, and munic-
ipal records. Patient follow-up for vital status was complete to the end of 2007
in most centers and to the end of 2008 in British Columbia, Canada, and
Torino, Italy.
Statistical Analysis
We examined the associations of clinical and pathologic characteristics
with TIL grade for melanomas in an analysis that included both SPMs and
MPMs. We used multinomial logistic generalized estimating equation regres-
sion models specifying an exchangeable working correlation structure to ac-
count for the clustering of melanomas for patients with MPMs. Robust
variance was used to obtain the CIs. TIL grade was treated as a nominal
response variable, and brisk and nonbrisk were simultaneously compared
with absent TIL grade. All models included study center and lesion status
(SPM, index MPM, or previous MPM), the design variables. Statistical
significance was assessed by using Wald tests. We also report results from
similar models examining the association of TIL grade with AJCC tumor
Table 1. Characteristics of 3,330 Primary Invasive Cutaneous Melanomas Centrally Scored for TIL Grade From 2,845 Patients
Characteristic
All SPMs and MPMs





No. % No. % No. % No. %
Sex
Male 1,940 58 982 51 464 69 494 67
Female 1,390 42 937 49 209 31 244 33
Age at diagnosis, years
Median 60 55 67 64
IQR 48-71 44-68 57-75 53-72
TIL grade
Absent 696 21 424 22 135 20 137 19
Nonbrisk 2,124 64 1,227 64 424 63 473 64
Brisk 510 15 268 14 114 17 128 17
NOTE. Patients who had TIL grades scored in their melanoma(s) were included.
Abbreviations: IQR, interquartile range; MPM, multiple primary melanoma; SPM, single primary melanoma; TIL, tumor-infiltrating lymphocyte.
TIL grades were scored on standardized review of slides stained with hematoxylin and eosin.
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stage. Linear trend was tested by using the Wald statistic when tumor stage
was treated as a single ordinal variable. Statistical analysis was performed
by using R software (version 2.15.0; R Development Core Team, Vienna,
Austria) with package multgee.
The association of TIL grade with survival was examined in all patients,
including those with SPMs and MPMs. For patients with MPMs with review
data for both the index and a previous MPM, we used the pathology charac-
teristics of the tumor with the greatest Breslow thickness in the analysis. When
thickness was the same for both melanomas, we used the characteristics of the
index MPM, and if one MPM had thickness missing, the pathology character-
istics of the other were used. Since the parent study involved population-based
ascertainment of incident SPMs and MPMs, survival time was accumulated
from the diagnosis date of the index lesion, whether SPM or MPM. The end
point was date of death or the end of complete follow-up (censored patients).
For melanoma-specific survival, patients were censored at the time of death as
a result of any cause other than melanoma.
Survival curves by TIL grade were constructed by using the Kaplan-
Meier method and compared by using a log-rank test. Hazard ratios (HRs) and
95% CIs for melanoma-specific survival by TIL grade were estimated in Cox
regression models. For 96 patients enrolled as patients with SPMs who expe-
rienced a subsequent melanoma during the period of participant recruitment,
a time-dependent covariate for MPM status was included in the Cox models at
the date of diagnosis of the subsequent melanoma. Linear trend was tested by
using the Wald statistic in which TIL grade was treated as a single ordinal
variable. An initial Cox model was adjusted for study center and whether SPM
or MPM, and another model also included age, sex, site, and tumor stage.
Scalp/neck and face/ears were included as separate covariates because previous
studies found that patients with scalp/neck melanomas had poorer survival
than patients with melanoma of other sites, including extremities, trunk, face,
and ears.19-21 The likelihood ratio test with an a priori alpha of .222 was used to
test interactions, comparing a model with main effects to a model with main
effects and interaction terms. Reanalysis was performed including only mela-
nomas in vertical growth phase and, separately, including only T1b or higher-
stage melanomas. A separate fully adjusted Cox model for overall survival by
TIL grade is also presented in Table 2.
Tests based on Schoenfeld residuals and graphical methods using
Kaplan-Meier curves showed no evidence that proportional hazards assump-
tions were violated for TIL grade. All significance tests were two-sided. SAS
version 9.3 (SAS Institute, Cary, NC) was used for all survival analyses except
for Kaplan-Meier curves and likelihood ratio test, which were implemented in
STATA/IC 12.1 (STATA, College Station, TX).
RESULTS
Clinicopathologic Features
The patients’ age, sex and TIL frequencies for the 3,330 melano-
mas scored for TIL grade are shown in Table 1. TIL grade was classified
as absent in 21%, nonbrisk in 64%, and brisk in 15% of melanomas.
We examined clinicopathologic characteristics in relationship to
TIL grade, simultaneously comparing nonbrisk and brisk to absent
TILs for 3,207 SPMs and MPMs with complete data for all variables in
Appendix Table A1 (online only) and Table 2. Nonbrisk and brisk TIL
grades were each positively associated (P  .05) with trunk/pelvis or
upper extremities, superficial spreading or lentigo maligna subtype,
thinner lesions, and absent mitoses, but not sex, adjusted for the
design variables of study center and lesion status (SPM, index MPM,
or previous MPM; Appendix Table A1). Brisk TIL grade, but not
nonbrisk grade, was also positively associated (each P  .05) with
younger age, absent ulceration, and radial growth adjusted for de-
sign variables.
When all variables were included in the model (Table 2), inde-
pendent predictors for nonbrisk TIL grade were trunk/pelvis or upper
extremity location, histologic subtypes other than unclassified/other,
and thinner lesions (each P  .05). Independent predictors for brisk
TIL grade were younger age, trunk/pelvis or upper extremity location,
thinner lesions, and radial growth phase (each P  .05). Breslow
thickness in the full model accounted for the effects of mitoses for
nonbrisk and brisk TIL grades and also ulceration for brisk TIL grade.
Age and Breslow thickness accounted for the effects of histologic
subtype for brisk TIL grade.
The relationship between TIL grade and individual AJCC tumor
stage categories was also examined (Table 3), adjusting for factors
known to be important for survival (age, sex, anatomic site) and the
design variables. Nonbrisk TIL grade was generally more likely among
lower-stage tumors, with odds ratios (ORs) of 1.1 for T1b and 1.4 for
T2b but ORs of 0.8 for T2a and T3b and 0.6 for T3a, T4a, and T4b
relative to T1a tumors (Ptrend  .001). Brisk TIL grade was also more
likely among lower-stage tumors, with ORs of 0.9 for T1b, 0.5 for T2a
and T2b, 0.3 for T3a, 0.2 for T3b, and 0.1 for T4a (Ptrend  .001); no
T4b melanomas had brisk TILs.
Melanoma-Specific Survival
There were 208 melanoma deaths in 2,728 GEM patients with
complete AJCC tumor stage information; the median follow-up time
was 7.6 years. The 5-year survival was 93% (95% CI, 91% to 95%) with
absent, 94% (95% CI, 93% to 95%) with nonbrisk, and 97% (95% CI,
95% to 99%) with brisk TIL grade (log-rank test P  .001; Fig 1). The
HRs for melanoma death were 0.7 (95% CI, 0.5 to 0.9) for nonbrisk
and 0.3 (95% CI, 0.2 to 0.5) for brisk relative to absent TIL grade in a
Cox regression model including only design variables (study center
and whether SPM or MPM; Ptrend  .001; not shown in tables). This
survival advantage with higher TIL grade persisted with the addition of
tumor stage, age, sex, and site to the model (HR, 0.7 for nonbrisk and
0.5 for brisk relative to absent TIL grade; Ptrend  .009; Table 4). No
significant interactions were found between TIL grade and age, sex,
site or stage in the fully adjusted model. Younger age, location other
than the scalp/neck, higher TIL grade, and lower tumor stage each
remained significantly associated with survival in the fully adjusted
model (P  .05), although sex did not (P  .15).
The majority of other studies have excluded radial growth phase
(RGP) melanomas from analyses examining TIL grades in relation-
ship to survival. Thus, we repeated our analysis with only the 1,741
patients with vertical growth phase melanomas who experienced 187
melanoma deaths, excluding 979 participants with RGP melanomas
and eight patients with missing data for growth phase (not shown in
tables). Again there was a melanoma survival advantage for nonbrisk
(HR, 0.7; 95% CI, 0.5 to 1.0) and brisk (HR, 0.5; 95% CI, 0.3 to 1.0)
TIL grade (Ptrend  .02) in a model with age, sex, site, tumor stage,
study center, and whether SPM or MPM. Among RGP melanoma
participants, there were 21 melanoma-related deaths, too few to
conduct a separate survival analysis; 2% (n  4) with absent; 3%
(n  14) with nonbrisk, and 1% (n  3) with brisk TIL grade died
from melanoma.
Because clinical decisions typically depend on tumor staging,23
we also performed an analysis limited to the 1,423 patients with T1b or
higher tumor stage who also experienced 187 melanoma deaths, ex-
cluding 1,305 patients with T1a melanomas who had 21 melanoma-
related deaths (not shown in tables). Among patients with T1b or
higher tumor stage, there remained a survival advantage for nonbrisk
(HR, 0.8; 95% 0.6 to 1.1) and brisk (HR, 0.4; 95% CI 0.2 to 0.9) TIL
Thomas et al
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grade (Ptrend  .01), adjusting for age, sex, site, tumor stage, study
center, and whether SPM or MPM. Among patients with T1a mela-
noma, 2% (n  5) with absent, 1% (n  12) with nonbrisk, and 2%
(n  4) with brisk TIL grade died from melanoma.
Overall Survival
Higher TIL grade was also associated with a lower risk of overall
death in a fully adjusted Cox model (Ptrend  .009; Appendix Table A2,
online only).
DISCUSSION
Melanoma location on the trunk and upper extremities and thinner
melanomas were each independently associated with nonbrisk and
brisk TIL grade in melanomas in the GEM study. Histologic subtypes
other than unclassified/other were independently associated with
nonbrisk TIL grade, and younger age and radial growth were indepen-
dently associated with brisk TIL grade. Nonbrisk and brisk TIL grades
were each more frequent among melanomas diagnosed with lower
AJCC tumor stage. Melanoma-specific fatality was 30% lower when
nonbrisk and 50% lower when brisk TIL grade was present after
adjustment for age, sex, site, tumor stage, center, and whether SPM or
MPM. Independent predictors for better melanoma-specific survival
were higher TIL grade, younger age, location other than scalp/neck,
and lower tumor stage; survival was the same in men and women in
the adjusted model.
The association of brisk TIL grade with younger age in GEM is in
concordance with Mandala et al10 and could be a result of innate
Table 2. Relationship Between TIL Grade and Clinical and Pathologic Features for 3,307 Primary Invasive Melanomas From 2,827 Patients
Characteristic







Fully Adjusted Nonbrisk TIL
Grade Fully Adjusted Brisk TIL Grade
No. % No. % No. % OR 95% CI P† OR 95% CI P†
Sex .41 .38
Male 381 55 1,233 58 316 62 Reference — Reference —
Female 309 45 875 42 193 38 0.9 0.8 to 1.1 0.9 0.7 to 1.2
Age at diagnosis, years .47 .009
 50 183 27 601 29 144 28 Reference — Reference —
50-69 293 42 878 42 241 47 0.9 0.7 to 1.1 0.8 0.6 to 1.1
 70 214 31 629 30 124 24 0.9 0.7 to 1.1 0.6 0.4 to 0.8
Anatomic site .02  .001
Trunk/pelvis 257 37 943 45 277 54 Reference — Reference —
Scalp/neck 57 8 123 6 27 5 0.6 0.4 to 0.9 0.5 0.3 to 0.8
Face/ears/other‡ 92 13 243 12 29 6 0.7 0.5 to 1.0 0.3 0.2 to 0.5
Upper extremities 117 17 371 18 100 20 0.9 0.7 to 1.2 0.9 0.6 to 1.2
Lower extremities 167 24 428 20 76 15 0.7 0.6 to 0.9 0.4 0.3 to 0.6
Histologic subtype .03 .10
Superficial spreading 433 63 1,466 70 380 75 Reference — Reference —
Nodular 76 11 193 9 28 6 0.9 0.6 to 1.3 1 0.6 to 1.8
Lentigo maligna 89 13 286 14 76 15 1.1 0.8 to 1.4 1.4 0.9 to 2.0
Unclassified/other§ 92 13 163 8 25 5 0.6 0.5 to 0.9 0.6 0.4 to 1.0
Breslow thickness, mm .04 .003
0.01-1.00 403 58 1,400 66 407 80 Reference — Reference —
1.01-2.00 151 22 407 19 74 15 0.8 0.6 to 1.0 0.7 0.5 to 1.1
2.01-4.00 90 13 206 10 26 5 0.6 0.4 to 0.9 0.5 0.3 to 0.9
 4.00 46 7 95 5 2 0 0.6 0.4 to 1.0 0.1 0.0 to 0.4
Ulceration .05 .62
Absent 623 90 1,910 91 492 97 Reference — Reference —
Present 67 10 198 9 17 3 1.4 1.0 to 1.9 0.9 0.5 to 1.6
Mitoses .24 .50
Absent 367 53 1,240 59 367 72 Reference — Reference —
Present 323 47 868 41 142 28 0.9 0.7 to 1.1 0.9 0.6 to 1.3
Growth phase .11 .009
Radial growth phase 255 37 807 38 321 63 Reference — Reference —
Vertical growth phase 435 63 1,301 62 188 37 1.2 1.0 to 1.6 0.6 0.5 to 0.9
NOTE. Invasive single melanomas and multiple melanomas (index and previous) were included. Melanomas with one or more data points missing for Breslow
thickness (n  3), ulceration (n  11), mitoses (n  1), and growth phase (n  8) were excluded. We used multinomial logistic generalized estimating equation
regression models specifying an exchangeable working correlation structure to account for the clustering of melanomas for patients with multiple primary
melanomas (MPMs). TIL grade was treated as a nominal response variable, and the brisk and nonbrisk TIL grades were simultaneously compared with the reference
(absent TIL grade).
Abbreviations: OR, odds ratio; TIL, tumor-infiltrating lymphocyte.
Included all variables in the table and adjusted for study center and lesion status (single primary melanoma, index MPM, or previous MPM).
†P values were calculated in the generalized estimating equation models.
‡Other includes melanomas on the head that are not otherwise specified.
§Other includes spindle cell, nevoid, and Spitzoid melanomas.
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immune system defects reported as part of the aging process.24 In
contrast to our finding of more frequent brisk and nonbrisk TILs in
trunk/pelvis and upper extremity melanomas, previous studies have
reported no association of TIL grade with melanoma site, but these
studies aggregated data from different sites.10,11 We report an inde-
pendent inverse association of nonbrisk TILs with unclassified/other
melanoma that remains to be confirmed.
Our study results support previous findings that higher TIL
grade is associated with thinner melanomas.5,8,10,11 We also report
an association of brisk TIL grade with radial growth phase inde-
pendent of thickness. As previously suggested, it is impossible to
determine the temporality of these associations by using cross-
sectional data available from pathology records11; the findings
could be due to the release by TILs of factors that inhibit tumor
growth or lead to tumor regression or to thicker melanomas elic-
iting local or systemic immunosuppression.
One population-based study found no correlation between TILs
and melanoma-specific survival.12 However, that study compared
TILs simply as present versus absent,12 in contrast to most other
studies, including ours, which report presence of TILs as either non-
brisk or brisk. In concordance with our results, several studies3,6,8,9
reported that higher TIL grades were independently associated with
better melanoma-specific survival. Previous studies have suggested
that survival differences based on TIL grade are mainly in melanomas
with vertical growth.25 This also appeared to be the case in our study,
and these differences were limited to T1b or higher-stage tumors. Few
deaths occurred in RGP only or T1a melanomas, each of which had a
high proportion of melanomas with higher TIL grades.
Major advantages of our study are its large sample size, which
allowed us to examine TIL grades separately, population-based case
ascertainment, comparatively long follow-up period, and standard-
ized pathology review. In addition, our observational period ended
before the US Food and Drug Administration approvals of new mel-
anoma therapies vemurafenib and ipilimumab in 2011.26,27 Because
BRAF-mutant primary melanomas have been reported to more fre-
quently have tumor lymphocytic infiltrates,28 any future survival
study of TIL grade in relationship to survival could be confounded by
BRAF-mutant targeted treatment.27
Observer error could have led to TIL grade misclassification, but
TIL grading has previously been found to have high interobserver
Table 3. Relationship Between TIL Grade and AJCC Tumor Stage for 3,317 Primary Invasive Melanomas From 2,836 Patients
AJCC Tumor Stage






(n  509) Adjusted Nonbrisk TIL Grade† Adjusted Brisk TIL Grade†
No. % No. % No. % OR 95% CI Ptrend‡ OR 95% CI Ptrend‡
T1a 324 47 1,108 52 335 66 Reference — .001 Reference —  .001
T1b 82 12 295 14 72 14 1.1 0.8 to 1.4 0.9 0.6 to 1.3
T2a 140 20 351 17 67 13 0.8 0.6 to 1.0 0.5 0.3 to 0.7
T2b 12 2 58 3 7 1 1.4 0.7 to 2.7 0.5 0.2 to 1.4
T3a 58 8 128 6 20 4 0.6 0.5 to 0.9 0.3 0.2 to 0.6
T3b 32 5 79 4 6 1 0.8 0.5 to 1.2 0.2 0.1 to 0.5
T4a 26 4 51 2 2 0 0.6 0.4 to 1.0 0.1 0.02 to 0.3
T4b 20 3 44 2 0 — 0.6 0.4 to 1.1 — —
NOTE. Invasive single melanomas and multiple melanomas (index and previous) except for 13 melanomas with missing data for stage were included. We used
multinomial logistic generalized estimating equation regression models specifying an exchangeable working correlation structure to account for the clustering of
melanomas for patients with multiple primary melanomas (MPMs). TIL grade was treated as a nominal response variable, and the brisk and nonbrisk TIL grades were
simultaneously compared with the reference (absent TIL grade).
Abbreviations: AJCC, American Joint Committee on Cancer; OR, odds ratio; TIL, tumor-infiltrating lymphocyte.
T1a, Breslow thickness  1.0 mm and absence of ulceration or mitoses; T1b, Breslow thickness  1.0 mm and presence of ulceration or mitoses; T2a, Breslow
thickness 1.01-2.0 mm without ulceration; T2b, Breslow thickness 1.01-2.0 mm with ulceration; T3a, Breslow thickness 2.01-4.0 mm without ulceration; T3b,
Breslow thickness 2.01-4.0 mm with ulceration; T4a, Breslow thickness  4.0 mm without ulceration; T4b, Breslow thickness  4.0 mm with ulceration.
†Adjusted for age ( 50, 50-69,  70 years), sex, anatomic site (scalp/neck, face/ears/other, trunk/pelvis, upper extremities, lower extremities), study center, and
lesion status (single primary melanoma, index MPM, or previous MPM).























Brisk 393 389 370 327 34
Nonbrisk 1,750 1,712 1,610 1,415 122
Absent 585 570 525 471 40





Fig 1. Kaplan-Meier melanoma-specific survival probabilities by tumor-
infiltrating lymphocyte grade are shown for patients with melanomas (n  2,728)
with median follow-up of 7.6 years. Patients with a single primary melanoma
were diagnosed in 2000 and those with multiple primary melanomas were
diagnosed from 1998 to 2003. Patient follow-up for vital status was complete to
the end of 2007 in most centers and to the end of 2008 in British Columbia,
Canada, and Torino, Italy. Thus, only patients with multiple primary melanomas
would have been followed longer than 8 years, which explains the decrease in
the number of participants at risk of death after 8 years in the table.
Thomas et al
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agreement,29 which we confirmed among our review pathologists.
However, we did not examine specific subpopulations of TILs or
markers of immune cell activation that appear promising for outcome
prediction.25,30,31 TILs, as we scored them, might have included cell
populations with both positive and negative effects on tumor immu-
nity.25 Further, we did not assess expression of costimulatory mole-
cules or their ligands, such as PD-1/PD-L1, which could allow
melanomas with TILs to escape immune destruction.32
We found TIL grade to predict survival independently of age, sex,
tumor site, and tumor stage, suggesting that TIL grade provides addi-
tional information. Survival differences based on TIL grade are mainly
for melanomas with T1b or higher tumor stage. The biologic mecha-
nisms underlying our observed associations of nonbrisk and/or brisk
TIL grades with age, site, lesion thickness, histologic subtype, and
growth phase are currently not well described. The importance of
improving our understanding of TILs is underscored by emerging
evidence that TILs may predict responses to immunotherapies,
including ipilimumab and PD-1/PD-L1 antibodies and cancer
vaccines.32-34 We conclude that TIL grade deserves further pro-
spective investigation to determine whether it should routinely be
included in primary melanoma pathology reports and future AJCC
staging revisions.
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(n  208) Fully Adjusted TIL Grade
No. % No. % HR 95% CI P Ptrend
TIL grade .009
Absent 524 90 61 10 Reference —
Nonbrisk 1,617 92 133 8 0.7 0.5 to 1.0
Brisk 379 96 14 4 0.5 0.3 to 0.9
Age, years .006
Increase in 10-year increments — — 1.2 1.0 to 1.3
Sex .15
Male 1,385 90 151 10 Reference —
Female 1,135 95 57 5 0.8 0.6 to 1.1
Anatomic site .004
Trunk/pelvis 1,129 93 89 7 Reference —
Scalp/neck 127 81 29 19 1.8 1.1 to 2.7
Face/ears/other† 252 89 32 11 1.1 0.8 to 1.7
Upper extremities 470 94 29 6 0.7 0.5 to 1.1
Lower extremities 542 95 29 5 0.7 0.4 to 1.1
AJCC tumor stage‡  .001
T1a 1,284 98 21 2 Reference —
T1b 373 97 13 3 2.1 1.1 to 4.2
T2a 465 90 52 10 6.0 3.6 to 10.0
T2b 56 80 14 20 13.4 6.8 to 26.4
T3a 165 82 37 18 10.0 5.8 to 17.2
T3b 78 72 30 28 17.1 9.7 to 30.3
T4a 58 76 18 24 12.1 6.3 to 23.1
T4b 41 64 23 36 22.6 12.3 to 41.5
NOTE. Of the 2,845 patients included in this study, patients with multiple primary melanomas (MPMs) who were missing TIL grade (n  109) or AJCC tumor stage
(n  8) for their selected (usually thicker) melanoma were excluded. Patients who entered the study as patients with single primary melanoma who developed a
subsequent melanoma were treated as time dependent.
Abbreviations: AJCC, American Joint Committee on Cancer; HR, hazard ratio; TIL, tumor-infiltrating lymphocyte.
The Cox model included TIL grade (absent, nonbrisk, brisk), age (continuous), sex, anatomic site, AJCC tumor stage, study center, and whether single primary
melanoma or MPM.
†Other includes melanomas on the head that are not otherwise specified.
‡T1a, Breslow thickness  1.0 mm and absence of ulceration or mitoses; T1b, Breslow thickness  1.0 mm and presence of ulceration or mitoses; T2a, Breslow
thickness 1.01-2.0 mm without ulceration; T2b, Breslow thickness 1.01-2.0 mm with ulceration; T3a, Breslow thickness 2.01-4.0 mm without ulceration; T3b,
Breslow thickness 2.01-4.0 mm with ulceration; T4a, Breslow thickness  4.0 mm without ulceration; T4b, Breslow thickness  4.0 mm with ulceration.
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GLOSSARY TERMS
AJCC/UICC-TNM staging: The TNM Classification of
Malignant Tumours (TNM) is a cancer staging system that de-
scribes the extent of cancer in a patient’s body. * T describes the
size of the tumor and whether it has invaded nearby tissue, * N
describes regional lymph nodes that are involved, * M describes
distant metastasis (spread of cancer from one body part to an-
other). TNM is developed and maintained by the International
Union Against Cancer (UICC) to achieve consensus on one glob-
ally recognized standard for classifying the extent of spread of
cancer. The TNM classification is also used by the American Joint
Committee on Cancer (AJCC). In 1987, the UICC and AJCC
staging systems were unified into a single staging system. Progno-
sis of a patient is defined by the TNM Classification.
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Table A1. Relationship Between TIL Grade and Clinical and Pathologic Features for 3,307 Primary Invasive Melanomas from 2,827 Patients
Characteristic
Nonbrisk TIL Grade Brisk TIL Grade
OR 95% CI P† OR 95% CI P†
Sex .33 .24
Male Reference — Reference —
Female 0.9 0.8 to 1.1 0.9 0.7 to 1.1
Age at diagnosis, years .29  .001
 50 Reference — Reference —
50-69 0.9 0.7 to 1.1 0.8 0.6 to 1.1
 70 0.8 0.6 to 1.1 0.5 0.4 to 0.7
Anatomic site .001  .001
Trunk/pelvis Reference — Reference —
Scalp/neck 0.6 0.4 to 0.8 0.4 0.3 to 0.7
Face/ears/other‡ 0.7 0.5 to 0.9 0.3 0.2 to 0.5
Upper extremities 0.9 0.7 to 1.1 0.8 0.6 to 1.1
Lower extremities 0.7 0.5 to 0.9 0.4 0.3 to 0.5
Histologic subtype  .001  .001
Superficial spreading Reference — Reference —
Nodular 0.8 0.6 to 1.0 0.4 0.2 to 0.6
Lentigo maligna 0.9 0.7 to 1.2 0.9 0.6 to 1.2
Unclassified/other§ 0.5 0.4 to 0.7 0.3 0.2 to 0.5
Breslow thickness, mm  .001  .001
0.01-1.00 Reference — Reference —
1.01-2.00 0.8 0.6 to 1.0 0.5 0.4 to 0.7
2.01-4.00 0.6 0.5 to 0.8 0.3 0.2 to 0.4
 4.00 0.6 0.4 to 0.8 0.04 0.01 to 0.17
Ulceration .89  .001
Absent Reference — Reference —
Present 1.0 0.7 to 1.3 0.3 0.2 to 0.5
Mitoses .01  .001
Absent Reference — Reference —
Present 0.8 0.7 to 0.9 0.4 0.3 to 0.6
Growth phase .36  .001
Radial growth phase Reference — Reference —
Vertical growth phase 0.9 0.8 to 1.1 0.4 0.3 to 0.5
NOTE. Invasive single melanomas and multiple melanomas (index and previous) were included. Melanomas with one or more data points missing for Breslow
thickness (n  3), ulceration (n  11), mitoses (n  1), growth phase (n  8), pigmentation (n  9), solar elastosis (n  98), or co-existing nevus (n  9) were
excluded. We used multinomial logistic generalized estimating equation regression models specifying an exchangeable working correlation structure to account for
the clustering of melanomas for patients with multiple primary melanomas (MPMs). TIL grade was treated as a nominal response variable, and the brisk and nonbrisk
TIL grade were simultaneously compared with the reference (absent TIL grade).
Abbreviations: OR, odds ratio; TIL, tumor-infiltrating lymphocyte.
Compared with absent TIL grade; adjusted for design variables of study center and lesion status (single primary melanoma, index MPM, or previous MPM) only.
†P values were calculated in the generalized estimating equation models.
‡Other includes melanomas on the head that are not otherwise specified.
§Other includes spindle cell, nevoid, and Spitzoid melanomas.
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(n  459) Fully Adjusted TIL Grade
No. % No. % HR 95% CI P Ptrend
TIL grade .009
Absent 470 80 115 20 Reference —
Nonbrisk 1,448 83 302 17 0.8 0.7 to 1.1
Brisk 351 89 42 11 0.6 0.4 to 0.9
Age, years  .001
Increase in 10-year increments — — 1.6 1.5 to 1.8
Sex .006
Male 1,196 78 340 22 Reference —
Female 1,073 90 119 10 0.7 0.6 to 0.9
Anatomic site .002
Trunk/pelvis 1,005 83 213 17 Reference —
Scalp/neck 109 70 47 30 1.3 0.9 to 1.8
Face/ears/other† 208 73 76 27 1.0 0.7 to 1.3
Upper extremities 429 86 70 14 0.8 0.6 to 1.0
Lower extremities 518 91 53 9 0.6 0.4 to 0.8
AJCC tumor stage‡  .001
T1a 1,176 90 129 10 Reference —
T1b 351 91 35 9 1.0 0.7 to 1.4
T2a 419 81 98 19 1.8 1.4 to 2.4
T2b 45 64 25 36 3.5 2.3 to 5.4
T3a 141 70 61 30 2.7 2.0 to 3.7
T3b 61 56 47 44 3.9 2.8 to 5.5
T4a 48 63 28 37 2.9 1.9 to 4.5
T4b 28 44 36 56 4.8 3.3 to 7.0
NOTE. Of the 2,845 patients included in this study, patients with multiple primary melanomas (MPMs) who had missing TIL grade (n  109) or AJCC tumor stage
(n  8) for their selected (usually thicker) melanoma were excluded. Patients who entered the study as patients with single primary melanomas who developed a
subsequent melanoma were treated as time dependent.
Abbreviations: AJCC, American Joint Committee on Cancer; HR, hazard ratio; TIL, tumor-infiltrating lymphocyte.
The Cox model included TIL grade (absent, nonbrisk, brisk), age (continuous), sex, anatomic site, AJCC tumor stage, study center, and whether single primary
melanoma or MPM.
†Other includes melanomas on the head that are not otherwise specified.
‡T1a, Breslow thickness  1.0 mm and absence of ulceration or mitoses; T1b, Breslow thickness  1.0 mm and presence of ulceration or mitoses; T2a, Breslow
thickness 1.01-2.0 mm without ulceration; T2b, Breslow thickness 1.01-2.0 mm with ulceration; T3a, Breslow thickness 2.01-4.0 mm without ulceration; T3b,
Breslow thickness 2.01-4.0 mm with ulceration; T4a, Breslow thickness  4.0 mm without ulceration; T4b, Breslow thickness  4.0 mm with ulceration.
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